A Phase 4 interventional study of Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension and Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution in Glaucoma, sponsored by Alcon Research. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-03-22.
Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing brinzolamide in Glaucoma — none open to participants now, none under way, none of them phase 3. brinzolamide · Glaucoma.
Among the 21 studies testing brinzolamide in Glaucoma, this one is the 17th largest by enrollment, is one of 2 that started in 2009, is one of 13 in phase 4, and was the 8th registered.
1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.
Browse Glaucoma studies →None of the 21 studies testing brinzolamide in Glaucoma is open now. The open studies under Glaucoma, anywhere →
brinzolamide: first FDA approval 1998 (AZOPT), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 61 across 964 interventional studies indexed under Glaucoma.
Median enrollment 112 across the 21 interventional studies. Of the 20 that completed or were terminated, 14 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 21 have an industry lead sponsor. The 7 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
93 studies in Glaucoma by Alcon: none open now, none under way, none of them phase 3. Of 92 finished, 35 (38%) have results posted.
Among the 93 studies in Glaucoma by Alcon, this one is the 69th largest by enrollment of the 77 interventional ones that give a count, is one of 6 that started in 2009, is one of 37 in phase 4, and was the 44th registered.
Alcon’s Glaucoma studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing brinzolamide in Glaucoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Alcon’s 93 in Glaucoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to compare the short term effects of two intraocular pressure (IOP) lowering medications on ocular perfusion pressure (OPP), ocular blood flow, intraocular pressure, and blood pressure in patients with glaucoma. Ocular perfusion pressure (OPP) is defined as the difference between arterial blood pressure (diastolic and systolic) and intraocular pressure. The primary efficacy assessment is based on diastolic ocular perfusion pressure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AZARGA, followed by COMBIGAN, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.
Drug: Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension · Drug: Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution
COMBIGAN, followed by AZARGA, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.
Drug: Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension · Drug: Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution
Drug page: Brinzolamide
Fixed combination ophthalmic suspension
Also known as: AZARGA™
Drug page: Brimonidine
Fixed combination ophthalmic solution
Also known as: COMBIGAN®
Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6
Diastolic ocular perfusion pressure (DOPP) is defined as the difference between diastolic arterial pressure and intraocular pressure. Diastolic arterial pressure was measured with a calibrated automated sphygmomanometer. Intraocular pressure was measured with a calibrated pneumatonometer. A lower DOPP indicates a lower optic blood supply, which can be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).
Time frame: Week 0, Week 6 (period-based)
Mean Change From Baseline in Circadian Diastolic Ocular Perfusion Pressure at Week 6
Circadian diastolic ocular perfusion pressure (COPP) is defined as the variations in diastolic OPP during the day and night. Diastolic ocular perfusion pressure was calculated at 7 timepoints over a 24-hour period. Changes in the diastolic ocular perfusion pressure rhythm throughout the day (outside the normal range) may affect glaucoma progression.
Time frame: Week 0, Week 6 (period-based)
Mean Change From Baseline in Mean Flow Value in the Superotemporal Peripapillary Retina at Week 6
Retinal perfusion assessments were made using Heidelberg Retinal Flowmetry (HRF). Assessments were made at 4 timepoints over a 12-hour period. Intensity of blood flow was measured in arbitrary units, with a higher number indicating an increased blood flow. An increase in ocular blood flow may reduce the risk of glaucoma progression.
Time frame: Week 0, Week 6 (period-based)
Mean Change From Baseline in Mean Flow Value in the Inverotemporal Peripapillary Retina at Week 6
Retinal perfusion assessments were made using Heidelberg Retinal Flowmetry (HRF). Assessments were made at 4 timepoints over a 12-hour period. Intensity of blood flow was measured in arbitrary units, with a higher number indicating an increased blood flow. An increase in ocular blood flow may reduce the risk of glaucoma progression.
Time frame: Week 0, Week 6 (period-based)
Mean Change From Baseline in Intraocular Pressure (IOP) at Week 6
Intraocular pressure (IOP) is defined as the fluid pressure inside the eye. Intraocular pressure was measured with a calibrated pneumatonometer at 7 time points over a 24-hour period. High IOP (outside the normal range) can be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).
Time frame: Week 0, Week 6 (period-based)
Mean Change From Baseline in Diastolic Blood Pressure at Week 6
Blood pressure is defined as the pressure exerted by circulating blood upon the walls of the blood vessels, that is, arterial pressure of the systemic circulation of blood. Diastolic blood pressure refers to the minimum pressure, that is, the pressure between heartbeats. Diastolic glood pressure was measured at 7 timepoints in a 24-hour period using a calibrated sphygmomonometer. Higher blood pressure (outside the normal range) can be a risk factor for developing cardiovascular events, such as heart attack, stroke, or heart failure. Lower blood pressure (outside the normal range) can be a risk factor for dizziness or fainting.
Time frame: Week 0, Week 6 (period-based)
Mean Change From Baseline in Systolic Blood Pressure at Week 6
Blood pressure is defined as the pressure exerted by circulating blood upon the walls of the blood vessels, that is, arterial pressure of the systemic circulation of blood. Systolic blood pressure refers to the maximum pressure, that is, the pressure while the heart is beating, and was measured at 7 timepoints in a 24-hour period using a calibrated sphygmomonometer. Higher blood pressure (outside the normal range) can be a risk factor for developing cardiovascular events, such as heart attack, stroke, or heart failure. Lower blood pressure (outside the normal range) can be a risk factor for dizziness or fainting.
Time frame: Week 0, Week 6 (period-based)
Mean Change From Baseline in Vascular Resistance in the Central Retinal Artery at Week 6
Vascular resistance in the central retinal artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.
Time frame: Week 0, Week 6 (period-based)
Mean Change From Baseline in Vascular Resistance in the Ophthalmic Artery at 6 Weeks
Vascular resistance in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.
Time frame: Week 0, Week 6 (period-based)
Mean Change From Baseline in End Diastolic Velocity in the Ophthalmic Artery at Week 6
End diastolic velocity in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.
Time frame: Week 0, Week 6 (period-based)
Mean Change From Baseline in Peak Systolic Velocity in the Ophthalmic Artery at Week 6
Peak systolic velocity in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.
Time frame: Week 0, Week 6 (period-based)
Mean Change From Baseline in Peak Systolic Velocity in the Central Retinal Artery at Week 6
Peak systolic velocity in the central retinal artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.
Time frame: Week 0, Week 6 (period-based)
Participants were recruited from and enrolled at one study center located in Greece.
| Milestone | AZARGA/COMBIGAN | COMBIGAN/AZARGA |
|---|---|---|
| Started | 17 | 18 |
| Completed | 16 | 17 |
| Not completed | 1 | 1 |
| Withdrew: Noncompliance | 1 | 0 |
| Withdrew: Pt decision unrelated to adverse event | 0 | 1 |
| Milestone | AZARGA/COMBIGAN | COMBIGAN/AZARGA |
|---|---|---|
| Started | 16 | 17 |
| Completed | 16 | 17 |
| Not completed | 0 | 0 |
| Milestone | AZARGA/COMBIGAN | COMBIGAN/AZARGA |
|---|---|---|
| Started | 16 | 17 |
| Completed | 16 | 16 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
Diastolic ocular perfusion pressure (DOPP) is defined as the difference between diastolic arterial pressure and intraocular pressure. Diastolic arterial pressure was measured with a calibrated automated sphygmomanometer. Intraocular pressure was measured with a calibrated pneumatonometer. A lower DOPP indicates a lower optic blood supply, which can be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).
| mmHg (millimeters of mercury) | AZARGA | COMBIGAN |
|---|---|---|
| Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6 | 2.6 ± 0.780 | 0.8 ± 0.779 |
Circadian diastolic ocular perfusion pressure (COPP) is defined as the variations in diastolic OPP during the day and night. Diastolic ocular perfusion pressure was calculated at 7 timepoints over a 24-hour period. Changes in the diastolic ocular perfusion pressure rhythm throughout the day (outside the normal range) may affect glaucoma progression.
| mmHg (millimeters of mercury) | AZARGA | COMBIGAN |
|---|---|---|
| 9:00 am | 2.8 ± 1.282 | 6.5 ± 1.282 |
| 1:00 pm | 3.0 ± 1.282 | 2.1 ± 1.282 |
| 5:00 pm | 4.4 ± 1.282 | 3.9 ± 1.282 |
| 9:00 pm | 4.5 ± 1.282 | 2.0 ± 1.282 |
| 12:00 am | 0.8 ± 1.282 | -5.6 ± 1.282 |
| 3:00 am | 0.3 ± 1.282 | -4.0 ± 1.282 |
| 6:00 am | 2.0 ± 1.296 | 0.9 ± 1.282 |
Retinal perfusion assessments were made using Heidelberg Retinal Flowmetry (HRF). Assessments were made at 4 timepoints over a 12-hour period. Intensity of blood flow was measured in arbitrary units, with a higher number indicating an increased blood flow. An increase in ocular blood flow may reduce the risk of glaucoma progression.
| Arbitrary Units | AZARGA | COMBIGAN |
|---|---|---|
| 9:00 am | -272.4 ± 146.294 | -43.5 ± 146.586 |
| 1:00 pm | -12.1 ± 142.844 | 248.9 ± 144.917 |
| 5:00 pm | -26.7 ± 144.914 | -51.3 ± 142.844 |
| 9:00 pm | 14.0 ± 148.317 | -33.2 ± 144.451 |
Retinal perfusion assessments were made using Heidelberg Retinal Flowmetry (HRF). Assessments were made at 4 timepoints over a 12-hour period. Intensity of blood flow was measured in arbitrary units, with a higher number indicating an increased blood flow. An increase in ocular blood flow may reduce the risk of glaucoma progression.
| Arbitrary Units | AZARGA | COMBIGAN |
|---|---|---|
| 9:00 am | 15.9 ± 92.064 | -70.0 ± 89.642 |
| 1:00 pm | -40.7 ± 89.642 | -89.2 ± 95.324 |
| 5:00 pm | -38.7 ± 88.363 | -69.1 ± 92.610 |
| 9:00 pm | 182.3 ± 92.064 | -91.0 ± 92.064 |
Intraocular pressure (IOP) is defined as the fluid pressure inside the eye. Intraocular pressure was measured with a calibrated pneumatonometer at 7 time points over a 24-hour period. High IOP (outside the normal range) can be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).
| mmHg (millimeters of mercury) | AZARGA | COMBIGAN |
|---|---|---|
| 9:00 am | -6.3 ± 0.661 | -6.5 ± 0.661 |
| 1:00 pm | -6.0 ± 0.661 | -6.5 ± 0.661 |
| 5:00 pm | -5.6 ± 0.661 | -5.2 ± 0.661 |
| 9:00 pm | -4.3 ± 0.661 | -4.9 ± 0.661 |
| 12:00 am | -1.9 ± 0.661 | -1.6 ± 0.661 |
| 3:00 am | -1.3 ± 0.661 | -0.6 ± 0.661 |
| 6:00 am | -2.3 ± 0.668 | -1.2 ± 0.661 |
Blood pressure is defined as the pressure exerted by circulating blood upon the walls of the blood vessels, that is, arterial pressure of the systemic circulation of blood. Diastolic blood pressure refers to the minimum pressure, that is, the pressure between heartbeats. Diastolic glood pressure was measured at 7 timepoints in a 24-hour period using a calibrated sphygmomonometer. Higher blood pressure (outside the normal range) can be a risk factor for developing cardiovascular events, such as heart attack, stroke, or heart failure. Lower blood pressure (outside the normal range) can be a risk factor for dizziness or fainting.
| mmHg (millimeters of mercury) | AZARGA | COMBIGAN |
|---|---|---|
| 9:00 am | -3.3 ± 1.315 | 0.6 ± 1.315 |
| 1:00 pm | -3.5 ± 1.315 | -4.3 ± 1.315 |
| 5:00 pm | -1.5 ± 1.315 | -0.9 ± 1.315 |
| 9:00 pm | -0.5 ± 1.315 | -2.1 ± 1.315 |
| 12:00 am | -1.4 ± 1.315 | -7.3 ± 1.315 |
| 3:00 am | -1.5 ± 1.315 | -3.8 ± 1.315 |
| 6:00 am | -0.5 ± 1.334 | -0.7 ± 1.315 |
Blood pressure is defined as the pressure exerted by circulating blood upon the walls of the blood vessels, that is, arterial pressure of the systemic circulation of blood. Systolic blood pressure refers to the maximum pressure, that is, the pressure while the heart is beating, and was measured at 7 timepoints in a 24-hour period using a calibrated sphygmomonometer. Higher blood pressure (outside the normal range) can be a risk factor for developing cardiovascular events, such as heart attack, stroke, or heart failure. Lower blood pressure (outside the normal range) can be a risk factor for dizziness or fainting.
| mmHg (millimeters of mercury) | AZARGA | COMBIGAN |
|---|---|---|
| 9:00 am | -4.2 ± 2.134 | 4.5 ± 2.134 |
| 1:00 pm | -2.6 ± 2.134 | -1.9 ± 2.134 |
| 5:00 pm | -2.9 ± 2.134 | -0.4 ± 2.134 |
| 9:00 pm | -1.4 ± 2.134 | -0.6 ± 2.134 |
| 12:00 am | -2.9 ± 2.134 | -12.2 ± 2.134 |
| 3:00 am | -2.9 ± 2.134 | -3.0 ± 2.134 |
| 6:00 am | -0.1 ± 2.165 | 3.0 ± 2.134 |
Vascular resistance in the central retinal artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.
| cm/s (centimeters per second) | AZARGA | COMBIGAN |
|---|---|---|
| 9:00 am | -0.00 ± 0.014 | 0.01 ± 0.014 |
| 1:00 pm | -0.01 ± 0.014 | 0.01 ± 0.014 |
| 5:00 pm | 0.00 ± 0.014 | -0.00 ± 0.014 |
| 9:00 pm | 0.00 ± 0.014 | 0.02 ± 0.014 |
| 12:00 am | 0.02 ± 0.014 | -0.01 ± 0.014 |
| 3:00 am | 0.01 ± 0.014 | 0.01 ± 0.014 |
| 6:00 am | -0.02 ± 0.014 | 0.02 ± 0.014 |
Vascular resistance in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.
| cm/s (centimeters per second) | AZARGA | COMBIGAN |
|---|---|---|
| 9:00 am | -0.01 ± 0.012 | -0.01 ± 0.011 |
| 1:00 pm | 0.02 ± 0.012 | 0.02 ± 0.012 |
| 5:00 pm | 0.01 ± 0.012 | 0.01 ± 0.012 |
| 9:00 pm | 0.01 ± 0.012 | 0.01 ± 0.011 |
| 12:00 am | -0.01 ± 0.012 | 0.02 ± 0.012 |
| 3:00 am | 0.01 ± 0.012 | 0.03 ± 0.012 |
| 6:00 am | 0.01 ± 0.012 | 0.03 ± 0.011 |
End diastolic velocity in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.
| cm/s (centimeters per second) | AZARGA | COMBIGAN |
|---|---|---|
| 9:00 am | -0.0 ± 0.454 | -0.8 ± 0.448 |
| 1:00 pm | -0.6 ± 0.459 | -1.2 ± 0.460 |
| 5:00 pm | 0.5 ± 0.459 | 0.2 ± 0.466 |
| 9:00 pm | 0.4 ± 0.454 | -0.8 ± 0.448 |
| 12:00 am | -0.8 ± 0.466 | -1.4 ± 0.454 |
| 3:00 am | -0.1 ± 0.454 | -0.6 ± 0.459 |
| 6:00 am | -0.2 ± 0.466 | -0.5 ± 0.448 |
Peak systolic velocity in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.
| cm/s (centimeters per second) | AZARGA | COMBIGAN |
|---|---|---|
| 9:00 am | -1.0 ± 1.237 | -3.8 ± 1.221 |
| 1:00 pm | -0.7 ± 1.251 | -1.4 ± 1.254 |
| 5:00 pm | 2.2 ± 1.251 | 1.3 ± 1.267 |
| 9:00 pm | 2.2 ± 1.237 | -1.4 ± 1.221 |
| 12:00 am | -2.3 ± 1.268 | -3.1 ± 1.235 |
| 3:00 am | 0.2 ± 1.235 | 0.0 ± 1.250 |
| 6:00 am | -0.6 ± 1.267 | 1.5 ± 1.221 |
Peak systolic velocity in the central retinal artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.
| cm/s (centimeters per second) | AZARGA | COMBIGAN |
|---|---|---|
| 9:00 am | 0.9 ± 0.571 | 0.7 ± 0.565 |
| 1:00 pm | -0.2 ± 0.577 | 0.3 ± 0.578 |
| 5:00 pm | 1.0 ± 0.577 | 0.6 ± 0.565 |
| 9:00 pm | 0.9 ± 0.565 | -0.5 ± 0.565 |
| 12:00 am | 1.9 ± 0.577 | -0.5 ± 0.565 |
| 3:00 am | 0.2 ± 0.565 | -1.1 ± 0.570 |
| 6:00 am | 0.2 ± 0.571 | 0.9 ± 0.565 |
Collected over Adverse events were collected for the duration of the study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AZARGA | — | 1/34 (2.9%) | 0/34 (0%) |
| COMBIGAN | — | 0/34 (0%) | 0/34 (0%) |
| Event | AZARGA | COMBIGAN |
|---|---|---|
| Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/34 | 0/34 |
This reporting group includes all enrolled participants.
| Age Continuous(years) | Overall |
|---|---|
| Mean | 65.2 ± 10.3 |
| Sex: Female, Male(Participants) | Overall |
|---|---|
| Female | 19 |
| Male | 16 |
| Region of Enrollment(participants) | Overall |
|---|---|
| Greece | 35 |
The record gives a start of Feb 2009, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Brinzolamide · Brimonidine